NCT00501605

Phase I Study With AZD2171 in Patients With Advanced Solid Malignant Tumors and Liver Metastases

A Phase I Single Centre 2-part Open Study to Assess the Safety and Tolerability of AZD2171 Following Single and Multiple Oral Doses in Patients With Advanced Solid Malignant Tumors and Liver Metastases

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Single centre recruiting approximately 80 patients who are given a rising single, followed by multiple, ascending oral dose of AZD2171, assessing the safety and tolerability of AZD2171 in patients with solid tumors and metastatic liver disease.

Conditions

• Advanced Solid Tumor
• Liver Metastases

Interventions

Type	Name	Description
DRUG	AZD2171

Timeline

• Start date: 2003-02-01
• Primary completion: 2005-04-01
• Completion: 2006-02-01
• First posted: 2007-07-16
• Last updated: 2011-01-21

Locations

1 site across 1 country: Germany